Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ximeijing (喜美净) is a veterinary combination spot-on solution developed by Hisun Animal Health for cats. It is a broad-spectrum antiparasitic formulation containing four active ingredients: fipronil, moxidectin, praziquantel, and s-methoprene. Ximeijing is indicated for the prevention and treatment of mixed parasitic infections in cats, including external parasites such as fleas (adults, eggs, and larvae) and ticks, as well as internal parasites such as heartworms, gastrointestinal nematodes (roundworms and hookworms), and tapeworms. It was approved by the Ministry of Agriculture and Rural Affairs of China in 2026.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fipronil + moxidectin + praziquantel + s-methoprene.